Dr. Newton-Cheh is a cardiologist seeing advanced heart failure patients and a cardiovascular geneticist evaluating patients with cardiomyopathy. He has an active laboratory conducting research on the root causes of heart failure, arrhythmias and hypertension.
- Centers & Specialties
- Cardiovascular Genetics
- Heart Failure & Cardiac Transplant Program
- Resynchronization and Advanced Cardiac Therapeutics Program
- Clinical Interests
- Heart failure
- Cardiovascular genetics
- Medical Education
- MD, Columbia University College of Physicians and Surgeons
- MPH, Harvard School of Public Health
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Internal Medicine
- Cardiovascular Disease
- Advanced Heart Failure and Transplant Cardiology
- Boston: Massachusetts General Hospital
- Waltham: Mass General Waltham
- Existing Patients
- Patient Gateway
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
Dr. Newton-Cheh is a cardiologist in the Heart Failure and Cardiac Transplant section and the Cardiovascular Genetics Program of the Massachusetts General Hospital Cardiology Division and an Assistant Professor of Medicine at Harvard Medical School. He sees patients with advanced heart failure and patients undergoing genetic evaluation of potentially familial cardiomyopathies.
Dr. Newton-Cheh is a faculty member of the Center for Genomic Medicine and the Cardiovascular Research Center. He is a complex trait geneticist and cardiovascular epidemiologist. The Newton-Cheh laboratory is focused on the study of hypertension, arrhythmias and heart failure. They are leveraging the growth of human genetics to identify DNA sequence variants that contribute to these common diseases, to translate these genetic findings to an improved understanding of human physiology through patient-oriented research and to define the role of genetic variants, alongside other clinical risk factors, in risk prediction at the population level.
- Research Summary
Dr. Newton-Cheh is faculty member of the Center for Genomic Medicine and the Cardiovascular Research Center. Dr. Newton-Cheh is a complex trait geneticist and cardiovascular epidemiologist. The Newton-Cheh laboratory is focused on the study of hypertension, arrhythmias and heart failure. We are leveraging the growth of human genetics to identify novel drug targets and the causes of drug toxicity and to improve prediction of cardiovascular risk in individual patients.
For more information on our work click here.
In papers receiving advance online publication in Nature Genetics, two international multi-institutional research teams, co-led by investigators at Massachusetts General Hospital, describe identifying a total of 44 novel gene sites associated with hypertension or high blood pressure.
Two international research studies, both led by investigators affiliated with MGH and the Broad Institute, have uncovered new information about genes that may increase the risk of serious cardiac arrhythmias.
A new report from MGH scientists and colleagues around the world finds that common variants in 28 regions of DNA are associated with blood pressure in human patients. Most of the identified regions were completely unsuspected, and several may lead to a totally new class of hypertension drugs.
Measurement of known biomarkers of cardiovascular disease slightly improves the ability to predict future heart attack or stroke in healthy individuals, but not enough to change preventive therapies.
MGH Hotline 06.12.09 At a time of unprecedented scientific progress and widening public support for clinical and translational research, young and mid-career investigators are faced with challenges of limited funding and competing personal and professional demands that cause many to abandon research careers, noted Janet Hall, MD, of the MGH Reproductive Endocrine Unit, at a May 28 panel discussion during MGH Clinical Research Day.
Scientists from Massachusetts General Hospital (MGH), as part of a major international research collaboration, have associated common variants in eight regions of DNA with blood pressure levels in human patients. Six of the identified regions have not previously been implicated in blood pressure regulation.
55 Fruit Street
Boston, MA 02114-2696